Zentalis Pharmaceuticals, Inc. (ZNTL)
| Market Cap | 2.00B |
| Revenue (ttm) | n/a |
| Net Income (ttm) | n/a |
| Shares Out | 37.96M |
| EPS (ttm) | n/a |
| PE Ratio | n/a |
| Forward PE | n/a |
| Dividend | n/a |
| Dividend Yield | n/a |
| Trading Day | January 15 |
| Last Price | $49.13 |
| Previous Close | $50.92 |
| Change ($) | -1.79 |
| Change (%) | -3.52% |
| Day's Open | 50.60 |
| Day's Range | 48.41 - 51.77 |
| Day's Volume | 287,522 |
| 52-Week Range | 23.20 - 57.97 |
Andreas Halvorsen (Trades, Portfolio) has revealed a reduction in his holding of Zentalis Pharmaceuticals Inc. (NASDAQ:ZNTL), according to GuruFocus' Real-Time Picks, a Premium feature.
NEW YORK and SAN DIEGO, Nov. 12, 2020 (GLOBE NEWSWIRE) -- Zentalis Pharmaceuticals, Inc. (Nasdaq: ZNTL), a clinical-stage biopharmaceutical company focused on discovering and developing small ...
Live webcast to be held on September 24th at 12:00 p.m. EDT Live webcast to be held on September 24th at 12:00 p.m. EDT
NEW YORK and SAN DIEGO, Sept. 01, 2020 (GLOBE NEWSWIRE) -- Zentalis Pharmaceuticals, Inc. (Nasdaq: ZNTL), a clinical-stage biopharmaceutical company focused on discovering and developing sma...
Closed initial public offering (IPO) of common stock, raising gross proceeds of ~$190.0 million Raised an additional ~$144.4 million in gross proceeds from recent follow-on offering Comple...
NEW YORK and SAN DIEGO, July 29, 2020 (GLOBE NEWSWIRE) -- Zentalis Pharmaceuticals, Inc. (Nasdaq: ZNTL), a clinical-stage biopharmaceutical company focused on discovering and developing smal...
NEW YORK and SAN DIEGO, July 27, 2020 (GLOBE NEWSWIRE) -- Zentalis Pharmaceuticals, Inc. (Nasdaq: ZNTL), a clinical-stage biopharmaceutical company focused on discovering and developing smal...
NEW YORK & SAN DIEGO, July 27, 2020 (GLOBE NEWSWIRE) -- Zentalis Pharmaceuticals, Inc. (Nasdaq: ZNTL), a clinical-stage biopharmaceutical company focused on discovering and developing small ...
NEW YORK and SAN DIEGO, July 01, 2020 (GLOBE NEWSWIRE) -- Zentalis Pharmaceuticals, Inc. (Nasdaq: ZNTL), a clinical-stage biopharmaceutical company focused on discovering and developing smal...
Health care companies and governments are racing to find a vaccine or other effective treatment for Covid-19 -- so investors have been piling into stocks like Gilead Sciences, Moderna and Nova...
NEW YORK and SAN DIEGO, June 15, 2020 (GLOBE NEWSWIRE) -- Zentalis Pharmaceuticals, Inc. (Nasdaq: ZNTL), a clinical-stage biopharmaceutical company focused on discovering and developing smal...
The company's share price has nearly tripled since its IPO less than two months ago. Is it too late to get in on the fun?
NEW YORK, SAN DIEGO and DURHAM, N.C., May 28, 2020 (GLOBE NEWSWIRE) -- Zentalis Pharmaceuticals, Inc. (Nasdaq: ZNTL) and Tavros Therapeutics, Inc., today announced a strategic collaboration ...
Zentera will be the sole licensee of three Zentalis discovered therapies for development and commercialization in China Zentera will be the sole licensee of three Zentalis discovered therapies...
Zentera will be the sole licensee of three Zentalis discovered therapies for development and commercialization in China Zentera will be the sole licensee of three Zentalis discovered therapies...
Completed initial public offering of common stock, raising approximately $190.0 million in gross proceeds
ZN-d5 is the Company’s fourth product candidate to receive IND clearance in five years ZN-d5 is the Company’s fourth product candidate to receive IND clearance in five years
These companies just raised significant cash to advance promising drug pipelines.
Biotech pharmaceutical company Zentalis Pharmaceuticals has launched a successful IPO that values the company at over $730 million.
About ZNTL
Zentalis Pharmaceuticals, a clinical-stage biopharmaceutical company, develops small molecule therapeutics for the treatment of various cancers in the United States. Its lead product candidate is the ZN-c5, an oral selective estrogen receptor degrader that is in a Phase I/II clinical trial for the treatment of advanced or metastatic breast cancer. The company also develops ZN-c3, an inhibitor of WEE1, a protein tyrosine kinase, which is in Phase I/II clinical trial for the treatment of advanced solid tumors; ZN-d5, a selective inhibitor of B-ce... [Read more...]
| Industry Biotechnology | IPO Date Apr 3, 2020 |
| CEO Dr. Anthony Y. Sun M.D. | Employees 110 |
| Stock Exchange NASDAQ | Ticker Symbol ZNTL |
Analyst Forecasts
According to 5 analysts, the average rating for ZNTL stock is "Strong Buy." The 12-month stock price forecast is 57.00, which is an increase of 16.02% from the latest price.